Schedule Now
(866) 589-8639

Research

Recent Publications

A Receptor Story: Insulin Resistance Pathophysiology and Physiologic Insulin Resensitization’s Role as a Treatment Modality

Physiologic Insulin Resensitization as a Treatment Modality for Insulin Resistance Pathophysiology

Physiologic hormone administration improves HbA1C in Native Americans with type 2 diabetes: A retrospective study and review of insulin secretion and action

Improved HOMA-IR Insulin Sensitivity and Glycemic Control Utilizing Physiologic Insulin Resensitization

Improved Kidney Function Following Physiologic Insulin Resensitization Treatment Modality

Case Series: Reversal of Diabetic Neuropathy Utilizing Physiologic Insulin Resensitization

Case Series: Reversal of Diabetic Retinopathy in two Patients Following the use of Physiologic Insulin Resensitization

Improved HOMA-IR Insulin Sensitivity and Glycemic Control Utilizing Physiologic Insulin Resensitization

Improved HOMA-IR Insulin Sensitivity and Glycemic Control Utilizing Physiologic Insulin Resensitization

Dynamic Diabetes Solutions: Physiologic Insulin Resensitization

A Receptor Story: Insulin Resistance Pathophysiology and Physiologic Insulin Resensitization’s Role as a Treatment Modality

Reversal of Diabetic Retinopathy in two Patients Following the use of Physiologic Insulin Resensitization

Physiologic Insulin Resensitization as a Treatment Modality for Insulin Resistance Pathophysiology

Dynamic Diabetes Solutions: Physiologic Insulin Resensitization

Improved Kidney Function Following Physiologic Insulin Resensitization Treatment Modality

Case Series: Reversal of Diabetic Neuropathy Utilizing Physiologic Insulin Resensitization

Other Publications

“Economic Costs of Diabetes in the U.S. 2017” (Published online in Diabetes Care Mar, 2018)

Per Brian Loveridge, MD; “Diabetes represents the most expensive medical condition in America. The prevalence continues to rise, with one out of two adults having either diabetes or pre-diabetes. Greater focus and attention is needed to address the complications of this epidemic that plagues both the U.S., and the world at large. We want to be a part of the solution with our physiologic insulin treatments.”

Link to Full Article

“ACP Recommends Less Intensive Glycemic Control Targets for Type 2 Diabetes” (Ann Internal Medicine, Mar 2018)

Per Brian Loveridge, MD; “The American College of Physicians revised its recommendations for blood sugar control in type 2 Diabetes from 6.5-7.0% HbA1c to 7.0-8.0%. These changes were made because tight control can lead to serious life-threatening low blood sugar episodes. Unfortunately, at higher ranges, it is well established that patients are at greater risk of developing diabetic complications (retinopathy, nephropathy, neuropathy, diabetic ulcers, etc.). Additional approaches are needed to reduce complications and help patients gain greater control. “
Link to Full Article

“Closing in on the Mechanism of Pulsatile Insulin Secretion” (Diabetes Mar 2018)

Per Brian Loveridge, MD; “The American Diabetes Association published this review article exploring the critical importance of physiologic insulin in carbohydrate metabolism. It is becoming increasingly apparent that when this signaling pathway breaks down, patients experience loss of insulin response, receptor lag, and decreasing receptor expression. We work with patients and providers to restore physiologic insulin, which in turn up-regulates metabolism and provides cells with the energy needed to function properly.”
Link to Full Article

Pin It on Pinterest

Privacy Policy